Back to Search Start Over

Annexin-V positive extracellular vesicles level is increased in severe COVID-19 disease.

Authors :
Jacob V
Lambour A
Swinyard B
Zerbib Y
Diouf M
Soudet S
Brochot E
Six I
Maizel J
Slama M
Guillaume N
Source :
Frontiers in medicine [Front Med (Lausanne)] 2023 Jun 02; Vol. 10, pp. 1186122. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
Publication Year :
2023

Abstract

Objectives: To evaluate extracellular vesicles levels in a cohort of SARS-CoV-2's patients hospitalized in an intensive care unit with and without COVID-19 associated thromboembolic events.<br />Methods: In this study, we aim to assess endothelial and platelet membrane-derived extracellular vesicles levels in a cohort of SARS-CoV-2 patients with and without COVID-19-associated thromboembolic events who were hospitalized in an intensive care unit. Annexin-V positive extracellular vesicles levels were prospectively assessed by flow cytometry in one hundred twenty-three critically ill adults diagnosed with acute respiratory distress syndrome associated with a SARS-CoV-2 infection, ten adults diagnosed for moderate SARS-CoV-2 infection and 25 healthy volunteers.<br />Results: On our critically ill patients, thirty-four patients (27.6%) had a thromboembolic event, Fifty-three (43%) died. Endothelial and platelet membrane-derived extracellular vesicles were drastically increased in SARS-CoV-2 patients hospitalized in the ICU compared to healthy volunteers. Moreover a slighty higher small/large ratio for platelets membrane-derived extracellular vesicles in patients was linked to thrombo-embolic events.<br />Conclusion: A comparison between total annexin-V positive extracellular vesicles levels in severe and moderate SARS-CoV-2 infection and healthy controls showed a significant increase in patients with severe infection and their sizes could be considered as biomarkers of SARS-CoV-2 associated thrombo-embolic events.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2023 Jacob, Lambour, Swinyard, Zerbib, Diouf, Soudet, Brochot, Six, Maizel, Slama and Guillaume.)

Details

Language :
English
ISSN :
2296-858X
Volume :
10
Database :
MEDLINE
Journal :
Frontiers in medicine
Publication Type :
Academic Journal
Accession number :
37332749
Full Text :
https://doi.org/10.3389/fmed.2023.1186122